Sorry, Your Requested Page Was Not Found.
Greetings! We apologize for the inconvenience, but the page, Press Release Myriad Genetics Announces Publication Of A Prospective Clinical Study Of The Endopredict Test In Women With Early Stage Breast Cancer is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3 - 18 months after the created date. We prefer to keep content fresh and current and not keep old news. Thanks for visiting today.Search RobinsPost News & Noticias
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Diaz, President and CEO, Myriad Genetics ... prospective trials. Myriad has announced several important research collaborations: a retrospective study of MRD efficacy in metastatic breast cancer ... Read More
Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
SALT LAKE CITY, March 20, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics ... on their arm, press the button, and the sample is collected in one to four minutes. Moreover, clinical studies have shown ... Read More
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
The ProActive study is the largest prospective dd-cfDNA study in ... These data further support the Prospera Kidney test’s value as an early indicator of rejection vs biopsy. Read More
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
The European study demonstrated high accuracy for the T2Resistance Panel, faster detection times, and the impact of faster test results on clinical ... The publication, A prospective observational ... Read More
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics ... interventional prospective trials. Myriad has announced several important research collaborations: a retrospective study of MRD ... Read More
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney ... Read More
Myriad Genetics, Inc.: Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Diaz, President and CEO, Myriad Genetics ... prospective trials. Myriad has announced several important research collaborations: a retrospective study of MRD efficacy in metastatic breast cancer ... Read More
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study ... Kidney test’s value as an early indicator of ... Read More
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
We believe the ProActive study provides robust evidence in support of regular surveillance with the Prospera dd-cfDNA test, which the industry has long been awaiting. Natera remains excited to ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus